Pasar al contenido principal

NUEVA GENERACION DE AGENTES INMUNOTERAPEUTICOS BASADOS EN MICOBACTERIAS NO TUBERCULOSAS MODIFICADAS

PID2021-122331OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth

  • Bach Griera, Marc|||0000-0001-9845-7225
  • Hernández, Alba|||0000-0001-6938-1233
  • Julián, Esther|||0000-0002-6558-3978
Bladder cancer (BC) is a highly recurrent and invasive malignancy, with Mycobacterium bovis BCG serving as the primary immunotherapy, particularly for non-muscle-invasive bladder cancer (NMIBC). However, the mechanisms underlying BCG's antitumor effects and the potential of non-tuberculous mycobacteria like Mycobacterium brumae remain unclear. This study investigates the antitumor effects of M. bovis BCG and M. brumae on BC cell migration, invasion, and anchorage-independent growth. BC cell lines representing different stages of tumor differentiation were treated with either M. bovis BCG or M. brumae. Cell migration was assessed through wound healing and transwell assays, invasiveness by transwell invasion assays, MMP-9 production by gelatin zymography, and anchorage-independent growth via soft agar colony formation. Both mycobacteria inhibited individual cell migration across all BC lines, while collective migration was only reduced in intermediate-grade cells. Both treatments also reduced invasiveness, associated with decreased MMP-9 production. Furthermore, M. brumae inhibited anchorage-independent growth across all BC lines, while M. bovis BCG had a more selective effect, primarily inhibiting growth in high-grade cells. In conclusion, both mycobacteria reduce migration, invasion, and anchorage-independent growth of BC cells, with their effectiveness varying by species and tumor differentiation grade.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Urease-powered nanobots for radionuclide bladder cancer therapy

  • Simó, Cristina|||0000-0002-5980-9379
  • Serra-Casablancas, Meritxell|||0000-0003-4806-3249
  • Hortelão, A. C. L.|||0000-0001-9269-0480
  • Di Carlo, Valerio|||0000-0002-5099-0685
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Plaza-García, Sandra
  • Rabanal Prados, Rosa Ma|||0000-0002-9521-791X
  • Ramos-Cabrer, Pedro|||0000-0003-0368-7031
  • Yagüe, Balbino
  • Aguado, Laura
  • Bardia, Lídia
  • Tosi, Sébastien
  • Gómez Vallejo, Vanessa|||0000-0003-3995-9596
  • Martín, Abraham
  • Patiño, Tania|||0000-0001-9979-7926
  • Julián, Esther|||0000-0002-6558-3978
  • Colombelli, Julien|||0000-0002-2784-4276
  • Llop, Jordi|||0000-0002-0821-9838
  • Sánchez Ordóñez, Samuel|||0000-0001-9713-9997
Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy. Bladder cancer treatment suffers from low therapeutic efficacy. Here the authors present radioactive 131 I-labelled urease-powered nanobots that exhibit enhanced accumulation at the tumour site, enabling effective radionuclide therapy at low doses as an alternative treatment option for bladder cancer.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero-Abadía, Paula
  • Ruiz-Rodríguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard
  • Chiner-Oms, Álvaro
  • Torres-Puente, Manuela
  • Comas, Iñaki
  • Julián, Esther
  • Coscollá, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential., This research was funded by the Spanish Ministry of Science, Innovation, and Universities (MICIN) and co-funded by the FEDER Funds (RTI2018-098777-B-I00, RTI2018-094399-A-I00, PID2021-125801OB-I00, PID2021-122331OB-I00, and PID2021-123443OB-I00), the AGAUR-Generalitat of Catalunya (2017SGR229 and 2017SGR-1079), Ramón y Cajal fellowship (RYC-2015-18213 MICIN), FPI fellowship (PRE-2019-088141 MICIN), Generalitat Valenciana (SEJI/2019/011), MycoNET (RED2018-102677-T), and the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Program (PTI+ Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model

  • Campo-Pérez, Víctor
  • Guallar-Garrido, Sandra
  • Cabrera-Rubio, Raúl
  • Herrero-Abadía, Paula
  • Seguí-Moll, Arnau
  • Torres-Puente, Manuela
  • Cano-Jiménez, Pablo
  • Comas, Iñaki
  • Torrents, Eduard
  • Julián, Esther
13 páginas, 8 figuras, The bladder microbiota may influence tumor progression and responses to intravesical therapies, yet the effects of Mycobacterium bovis BCG instillations on bladder and gut microbiota remain unexplored. This study evaluates, for the first time, the impact of M. bovis BCG and Mycobacterium brumae, a non-pathogenic immunomodulator, on microbiota composition in bladder tissue and cecal stool of healthy and tumor-bearing mice. Mycobacterial instillations increased gut microbial richness but reduced Actinobacteria. In tumor-bearing mice, Muribaculaceae and Bacteroidaceae were enriched, while M. bovis BCG reduced Muribaculaceae and increased Rikenellaceae. In the bladder, M. brumae instillations favored Staphylococcaceae in healthy mice, while Enterococcaceae dominated most groups except M. bovis BCG-treated tumor-bearing mice. Escherichia/Shigella decreased in mycobacteria-treated tumor-bearing mice, while Burkholderia was more prevalent in untreated bladders. Notably, M. brumae increased stool alpha diversity, whereas M. bovis BCG reduced bladder richness. These findings reveal that intravesical mycobacterial therapy modulates microbiota composition across body sites, underscoring the complex host-tumor-immunotherapy interplay., R.C.-R. thanks Generalitat-Valenciana (GVA) for the grant Plan GenT-Talent Attraction program (CDEIGENT 2020). V.C.-P. and A.S.-M. acknowledge AGAUR (Generalitat de Catalunya) for their support through the FI fellowship (2019 FI_B 00320 and 2022 FI_B 00822) during the period in which this work was carried out. This research was funded by grants PID2021-122331OB-I00, PID2021-125801OB-100, PID2024-158933OB-I00, PLEC2022-009356, PID2022-137607OB-I00, and PDC2022-133577-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE, MycoNET (RED2018-102677-T and RED-153634-T) and the CERCA program and AGAUR-Generalitat de Catalunya (2021SGR-01545 and 2021SGR-0092). RCR thanks Generalitat-Valenciana for the grant Plan GenT project (CDEIGENT 2020-02) and the Spanish government MCIN/AEI to the IATA-CSIC as Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/MCIN/AEI/10.13039/501100011033). E.T. is a researcher of the ICREA Academia 2025 program. E.J. is a Serra-Húnter fellow.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The high plasticity of nonpathogenic Mycobacterium brumae induces rapid changes in its lipid profile during pellicle maturation, The potential of this bacterium as a versatile cell factory for lipid compounds of therapeutic interest

  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Guallar Garrido, Sandra|||0000-0002-9666-5757
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Julián, Esther|||0000-0002-6558-3978
The immunomodulatory potential of mycobacteria to be used for therapeutic purposes varies by species and culture conditions and is closely related to mycobacterial lipid composition. Although the lipids present in the mycobacterial cell wall are relevant, lipids are mainly stored in intracellular lipid inclusions (ILIs), which have emerged as a crucial structure in understanding mycobacteria-host interaction. Little is known about ILI ultrastructure, production, and composition in nonpathogenic species. In this study, we compared the lipid profiles of the nonpathogenic immunomodulatory agent Mycobacterium brumae during pellicle maturation under different culture conditions with qualitative and quantitative approaches by using high-resolution imaging and biochemical and composition analyses to understand ILI dynamics. The results showed wax esters, mainly in early stages of development, and acylglycerols in mature ILI composition, revealing changes in dynamics, amount, and morphometry, depending on pellicle maturation and the culture media used. Low-glycerol cultures induced ILIs with lower molecular weights which were smaller in size in comparison with the ILIs produced in glycerol-enriched media. The data also indicate the simple metabolic plasticity of lipid synthesis in M. brumae, as well as its high versatility in generating different lipid profiles. These findings provide an interesting way to enhance the production of key lipid structures via the simple modulation of cell culture conditions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero Abadía, Paula|||0000-0001-9747-1818
  • Ruiz-Rodriguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard|||0000-0002-3010-1609
  • Chiner-Oms, Álvaro|||0000-0002-0463-0101
  • Torres-Puente, Manuela|||0000-0002-8352-180X
  • Comas, I.|||0000-0001-5504-9408
  • Julián, Esther|||0000-0002-6558-3978
  • Coscolla, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384 T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A high-throughput microtiter plate screening assay to quantify and differentiate species in dual-species biofilms

  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Alcàcer-Almansa, Júlia|||0000-0002-8688-3128
  • Julián, Esther|||0000-0002-6558-3978
  • Torrents, Eduard|||0000-0002-3010-1609
Pathogenic bacteria form biofilms during infection, and polymicrobial biofilms are the most frequent manifestation. Biofilm attachment, maturation, and/or antibiotic sensitivity are mainly evaluated with microtiter plate assays, in which bacteria are stained to enable the quantification of the biomass by optical absorbance or fluorescence emission. However, using these methods to distinguish different species in dual-species or polymicrobial biofilms is currently impossible. Colony-forming unit counts from homogenized dual-species biofilms on selective agar medium allow species differentiation but are time-consuming for a high-throughput screening. Thus, reliable, feasible, and fast methods are urgently needed to study the behavior of polymicrobial and dual-species communities. This study shows that Pseudomonas aeruginosa and Burkholderia cenocepacia strains expressing specific fluorescent or bioluminescent proteins permit the more efficient study of dual-species biofilms compared to other methods that rely on measuring the total biomass. Combining fluorescence and bioluminescence measurements allows an independent analysis of the different microbial species within the biofilm, indicating the degree of presence of each one over time during a dual-species biofilm growth. The quantitative strategies developed in this work are reproducible and recommended for dual-species biofilm studies with high-throughput microtiter plate approaches using strains that can constitutively express fluorescent or bioluminescent proteins.